pirinixic acid has been researched along with Osteoarthritis in 3 studies
pirinixic acid: structure
Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
Excerpt | Relevance | Reference |
---|---|---|
"To characterize the inhibitory effects of therapeutic concentrations of the nonsteroidal antiinflammatory drug nimesulide (NIM) on peroxisome proliferator-activated receptor (PPAR)-induced cyclooxygenase 2 (COX-2) gene expression in human synovial fibroblasts (HSFs) from patients with osteoarthritis (OA) and to define the intracellular mechanisms mediating the response." | 3.71 | Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. ( Di Battista, JA; Fahmi, H; Faour, WH; He, QW; Kalajdzic, T; Martel-Pelletier, J; Pelletier, JP, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Zhou, Y | 1 |
Chen, X | 1 |
Qu, N | 1 |
Zhang, B | 1 |
Xia, C | 1 |
Huang, D | 1 |
Zhao, Q | 1 |
Liu, H | 1 |
Guo, Y | 1 |
Xu, H | 1 |
Kalajdzic, T | 1 |
Faour, WH | 1 |
He, QW | 1 |
Fahmi, H | 1 |
Martel-Pelletier, J | 1 |
Pelletier, JP | 1 |
Di Battista, JA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
Intervention | Participants (Count of Participants) |
---|---|
Fenofibrate + Usual Care | 19 |
Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 5.03 |
Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
Intervention | days (Median) |
---|---|
Fenofibrate + Usual Care | 30 |
Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
Intervention | days (Mean) |
---|---|
Fenofibrate + Usual Care | 28.8 |
Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
Intervention | Ranked Severity Score (Median) |
---|---|
Fenofibrate + Usual Care | 5.32 |
Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 5.05 |
Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 1 |
Placebo + Usual Care | 1 |
3 other studies available for pirinixic acid and Osteoarthritis
Article | Year |
---|---|
Chondroprotection of PPARα activation by WY14643 via autophagy involving Akt and ERK in LPS-treated mouse chondrocytes and osteoarthritis model.
Topics: Animals; Anticholesteremic Agents; Autophagy; Cartilage, Articular; Chondrocytes; Disease Models, An | 2019 |
PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway.
Topics: Anti-Inflammatory Agents; Cells, Cultured; Chemokine CCL2; Dinoprostone; Endothelin-1; Fibroblasts; | 2016 |
Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.
Topics: Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA-Bindi | 2002 |